Research and Markets: Genzyme Corporation - SWOT Analysis of One of the World's Leading Biotechnology Companies

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/74ae87/genzyme_corporatio) has announced the addition of the "Genzyme Corporation - SWOT Analysis" company profile to their offering.

The Genzyme Corporation - SWOT Analysis company profile is the essential source for top-level company data and information. Genzyme Corporation - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Genzyme (the company) is one of the world's leading biotechnology companies. The company offers medicines for rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. The company primarily operates in the US and Europe. It is headquartered in Cambridge, Massachusetts and employed 12,000 people as of December 2009. The company recorded revenues of $4,515.5 million during the financial year (FY) ended December 2009, a decrease of 1.9% over FY2008. The operating profit of the company was $503.7 million during FY2009, a decrease of 13.4% over FY2008. The net profit of the company was $422.3 million in FY2009, an increase of 0.3% over FY2008.

Scope of the Report

  • Provides all the crucial information on Genzyme Corporation required for business and competitor intelligence needs
  • Contains a study of the major internal and external factors affecting Genzyme Corporation in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Genzyme Corporation
  • Data is supplemented with details on Genzyme Corporation history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Genzyme Corporation

Reasons to Purchase

  • Support sales activities by understanding your customers businesses better
  • Qualify prospective partners and suppliers
  • Keep fully up to date on your competitors business structure, strategy and prospects
  • Obtain the most up to date company information available

Key Topics Covered:

SWOT COMPANY PROFILE: Genzyme Corporation

Key Facts: Genzyme Corporation

Company Overview: Genzyme Corporation

Business Description: Genzyme Corporation

Company History: Genzyme Corporation

Key Employees: Genzyme Corporation

Key Employee Biographies: Genzyme Corporation

Products & Services Listing: Genzyme Corporation

Products & Services Analysis: Genzyme Corporation

SWOT analysis: Genzyme Corporation

  • Strengths: Genzyme Corporation
  • Weaknesses: Genzyme Corporation
  • Opportunities: Genzyme Corporation
  • Threats: Genzyme Corporation

Company View: Genzyme Corporation

Top Competitors: Genzyme Corporation

Location and Subsidiary: Genzyme Corporation

  • Head Office: Genzyme Corporation
  • Other Locations and Subsidiaries: Genzyme Corporation

For more information visit http://www.researchandmarkets.com/research/74ae87/genzyme_corporatio

Source: Datamonitor



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.